巢蛋白基因沉默通过激活细胞周期依赖性激酶（cdk5）促进大鼠神经胶质瘤细胞C6的迁移和增殖

中间纤维蛋白巢蛋白(nestin)在各种胚胎前体细胞及成熟组织中均有表达.近年一些研究显示,巢蛋白的表达上调和一些恶性肿瘤的病理特征有相关性.但是,巢蛋白在干细胞分化及肿瘤发生中的作用还不为人知.在本研究中,我们运用短发卡状的RNA为工具,以大鼠神经胶质瘤细胞系C6为模型,对巢蛋白的功能进行了研究.划痕实验和迁移实验的结果均显示,巢蛋白基因沉默可以促进C6细胞的迁移.同时,BrdU渗入实验显示,此过程伴随着细胞增殖的增加.进一步研究显示,细胞周期依赖性激酶cdk5的活性在此过程中有显著的增加.此外,巢蛋白基因沉默所引起的迁移改变可以被cdk5特异性抑制剂roscovitine所回复, 而对细胞增殖则没有显著影响.综上所述,本研究揭示了巢蛋白基因沉默与神经胶质瘤细胞的迁移和增殖相关,而cdk5是此过程的重要调节因子.     

瑞舒伐他汀对载脂蛋白E基因敲除小鼠动脉粥样硬化中调节性T细胞的影响

目的：探讨瑞舒伐他汀对载脂蛋白E基因敲除（ApoEKO）小鼠动脉粥样硬化中调节性T细胞的影响。方法：首先将30只ApoEKO小鼠建立动脉粥样硬化模型,随机分为高胆固醇饮食组（对照组）、瑞舒伐他汀低剂量组和瑞舒伐他汀高剂量组,各组分别给予蒸馏水或瑞舒伐他汀进行干预8周;将主动脉根部行冰冻切片油红染色,评估粥样硬化斑块面积大小;免疫组织化学法检测主动脉根部粥样硬化斑块处调节性T细胞（Treg）的表达。结果：各组小鼠均有动脉粥样硬化斑块形成,采用瑞舒伐他汀治疗的小鼠动脉粥样硬化斑块的面积明显小于未经治疗的小鼠（P〈0.01）,同时瑞舒伐他汀能明显增加粥样硬化病变处调节性T细胞的表达,且呈现剂效关系。结论：本实验观察到瑞舒伐他汀不仅能减小ApoEKO小鼠的主动脉粥样硬化斑块,且能使调节性T细胞的表达增多,推测瑞舒伐他汀可以通过促进调节性T细胞的生成而起到抑制动脉粥样硬化的作用。     

小鼠Daintain/AIF-1基因启动子的克隆及其荧光素酶报告基因载体的构建

目的：对Daintain/AIF-1（大炎肽/同种异体移植炎症因子-1）基因启动子进行克隆并构建荧光素酶报告基因载体,为进一步研究Daintain/AIF-1的转录调控作用提供了质粒资源。方法：提取单核巨噬细胞系RAW264.7基因组DNA,以其为模板采用PCR方法克隆出Daintain/AIF-1基因5＇端UTR区1.6 kb DNA序列,将该序列同源重组到pGL3-Basic载体上,转化感受态DH5α并酶切鉴定和测序。结果：PCR产物片段与预期结果一致,Daintain/AIF-1基因5＇端UTR区1.6 kb DNA序列连接到pGL3-Basic载体上,构建成pGL3-Basic-Daintain/AIF-1（pGL3-Basic-DT）载体,酶切结果与理论预测值一致,经测序证实无碱基突变。结论：Daintain/AIF-1基因报告基因载体的构建为进一步研究Daintain/AIF-1转录调控作用提供了载体资源。     

我国人粒细胞无形体病的研究进展

人粒细胞无形体病是由嗜吞噬细胞无形体引起的一种经蜱传播的人畜共患病。近年来,在美国、欧洲、非洲等地均有相关病例报道,我国也有病例发现。该病主要引起发热,血小板减少,严重可引起多脏器损害,甚至死亡。因此日益受到研究者们的关注与重视。本文分别从HGA的发现,临床特点,治疗,预防等方面介绍人粒细胞无形体病的研究进展。     

小鼠Daintain/AIF-1 基因启动子的克隆及其荧光素酶报告基因 载体的构建

目的:对Daintain/AIF-1(大炎肽/同种异体移植炎症因子-1)基因启动子进行克隆并构建荧光素酶报告基因载体,为进一步研究Daintain/AIF-1的转录调控作用提供了质粒资源。方法:提取单核巨噬细胞系RAW264.7基因组DNA,以其为模板采用PCR方法克隆出Daintain/AIF-1基因5’端UTR区1.6 kb DNA序列,将该序列同源重组到pGL3-Basic载体上,转化感受态DH5α并酶切鉴定和测序。结果:PCR产物片段与预期结果一致,Daintain/AIF-1基因5’端UTR区1.6 kb DNA序列连接到pGL3-Basic载体上,构建成pGL3-Basic-Daintain/AIF-1(pGL3-Basic-DT)载体,酶切结果与理论预测值一致,经测序证实无碱基突变。结论:Daintain/AIF-1基因报告基因载体的构建为进一步研究Daintain/AIF-1转录调控作用提供了载体资源。     

电磁场的应用与研究进展

随着生物医学工程学发展,物理疗法已经成为当前疾病治疗一个重要手段,因此电磁场治疗及生物电磁的研究成为当前热点。特别是在骨病等相关领域的研究,研究发现电磁场能有效的治疗和预防骨质疏松症。因此本文就电磁场治疗以及机理研究方面进行综述。     

Novel insulin-elicited phosphoproteins in adipocytes

Akt is a key insulin-activated protein kinase. We searched for Akt substrates in 3T3-L1 adipocytes by means of immunoprecipitation with an Akt phosphomotif-specific antibody (PAS antibody). Four insulin-elicited phosphoproteins were isolated and identified by mass spectrometry. The identity of each protein was established by isolating the protein from lysates of untreated and insulin-treated adipocytes with an antibody specific for the protein and showing that the PAS antibody reacted only with the protein in the immunoprecipitate from insulin-treated cells. These proteins have sizes of 47, 75, 105, and 250 kDa on SDS PAGE, and have been designated pp47, 75, 105, and 250. The effect of inhibitors on the phosphorylation of the proteins, the identified sites of phosphorylation, and in vitro phosphorylation by recombinant Akt further indicated that pp47, 105, and 250 are likely to be Akt substrates, whereas pp75 may not be. pp47 and 105 are novel proteins with no known or predicted function. pp75 was previously found as a protein that associated with the colony-stimulating factor receptor, designated as Fms-interacting protein. pp250 is a novel protein with a predicted GTPase activating protein (GAP) domain for Rheb and/or Rap at its carboxy terminus. The subcellular and tissue distributions of the four proteins were determined.     

Covalent modification of human homeodomain interacting protein kinase 2 by SUMO-1 at lysine 25 affects its stability

The HIPK2 protein is a critical regulator of apoptosis and functionally interacts with p53 to increase gene expression. Here we show that human HIPK2 is modified by sumoylation at lysine 25, as revealed by in vivo and in vitro experiments. While SUMO-1 modification of HIPK2 has no influence on its ability to phosphorylate p53 at serine 46, to induce gene expression, and to mediate apoptosis, a non-sumoylatable HIPK2 mutant displays a strongly increased protein stability. The N-terminal SUMO-1 modification site is conserved between all vertebrate HIPK2 proteins and is found in all members of the HIPK family of protein kinases. Accordingly, also human HIPK3 is modified by sumoylation.